Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Ospemifene in VVA (No Uterus)
NCT01586364Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2006
- Primary completion
- Nov 2008
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of ospemifene in vulvovaginal atrophy (VVA), sponsored by Shionogi & Co., Ltd. Primary endpoints: Incidence of Adverse Events (AEs), Change From Baseline in Serum Lipid Levels at Week 52 and 9 more. Started May 2006; status: completed.
02
Drugs
ospemifene
03
Conditions
vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT01586364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01586364.